Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Madrigal Pharmaceuticals (MDGL) Enterprise Value (2019 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Enterprise Value for 13 consecutive years, with -$203.8 million as the latest value for Q4 2025.

  • Quarterly Enterprise Value fell 94.04% to -$203.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$203.8 million through Dec 2025, down 94.04% year-over-year, with the annual reading at -$203.8 million for FY2025, 94.04% down from the prior year.
  • Enterprise Value for Q4 2025 was -$203.8 million at Madrigal Pharmaceuticals, up from -$1.1 billion in the prior quarter.
  • The five-year high for Enterprise Value was -$99.9 million in Q4 2023, with the low at -$1.1 billion in Q3 2025.
  • Average Enterprise Value over 5 years is -$463.9 million, with a median of -$303.2 million recorded in 2021.
  • The sharpest move saw Enterprise Value surged 72.15% in 2023, then tumbled 329.79% in 2024.
  • Over 5 years, Enterprise Value stood at -$270.3 million in 2021, then crashed by 32.71% to -$358.8 million in 2022, then skyrocketed by 72.15% to -$99.9 million in 2023, then fell by 5.11% to -$105.0 million in 2024, then plummeted by 94.04% to -$203.8 million in 2025.
  • According to Business Quant data, Enterprise Value over the past three periods came in at -$203.8 million, -$1.1 billion, and -$797.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.